Actively Recruiting

Phase Not Applicable
Age: 22Years +
All Genders
ID07543367

INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study

Led by Synchron, Inc. · Updated on 2026-05-11

10

Participants Needed

5

Research Sites

130 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the Synchron BCI motor neuroprosthesis, an implanted brain-computer interface designed for people with bilateral upper-limb motor impairment, such as those caused by Amyotrophic Lateral Sclerosis (ALS). The device aims to replace motor neuron function by detecting and transmitting brain signals to help users control digital devices. This early feasibility study focuses on understanding the safety and potential of this technology for individuals with ALS and related motor neuron diseases. The study involves implanting the Stentrode device, an endovascular electrode array that senses electrical signals from the brain's sensorimotor areas. Participants receive this implant and are then monitored over time. The study includes a single treatment arm where the device is implanted, followed by assessments at various time points up to one year post-implantation to evaluate device safety and function. Participants will be involved in clinical testing visits and training both at the study site and in their homes, supported by caregivers. Researchers will track serious adverse events related to the device up to one year after implantation. Imaging tests such as CT venography will assess the blood vessel condition and device position at six months and one year. The study duration and follow-up involve regular evaluations to monitor safety and device performance.

CONDITIONS

Brief Title

INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study

Who Can Participate

Age: 22Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to provide informed consent to participate in the study.
  • Diagnosis of ALS, with bilateral upper-limb paresis.
  • ALS must be refractory to treatment and have been present for a minimum of six months.
  • Aged 22 years or older.
  • Life expectancy greater than 12 months post-implantation.
  • Preserved precentral gyrus assessed using CT.
  • Suitable vascular anatomy assessed using CT venography.
  • Suitable anatomy for subcutaneous pocket creation.
  • Able to undergo anesthesia.
  • Willing and able to comply with all investigational requirements, including clinical testing visits and training visits in the home.
  • Caregiver(s) willing and able to facilitate study visits, including visits to the study site and in the home, and BCI use outside of study visits (e.g., device charging).
  • Patient and caregiver fluent in English.
  • Suitable home environment for BCI training.
Not Eligible

You will not qualify if you...

  • Active infection or unexplained fever in the 48 hours prior to informed consent.
  • Major psychiatric disorder that may adversely impact the participant's safety or study compliance, including severe depression, psychotic features, personality disorder, severe emotional lability, or substance abuse.
  • Diagnosis of ALS-FTD or another dementia.
  • Active implanted device (e.g., deep brain stimulator, cardiac defibrillator, pacemaker, vagal nerve stimulator, spinal cord stimulator, diaphragmatic pacer, etc.).
  • Known allergy to patient-contacting materials included in the implanted device.
  • Contraindication to angiographic imaging or iodine contrast media.
  • History of central venous sinus thrombosis.
  • Recent history of new venous thromboembolic event (in the 6 months prior to implant), recurrent history of venous thromboembolic disease, or hypercoagulable state.
  • Contraindication to antithrombotic therapy.
  • Participant is at substantially increased risk of infection, including immunocompromised status, recurrent or chronic infection, or poorly controlled diabetes mellitus.
  • Significant risk of non-healing of the subcutaneous pocket incision, including history of chronic non-healing surgical wounds or poorly controlled diabetes mellitus.
  • Pregnant or breast feeding.
  • Patients who are currently enrolled in any other clinical trial that would confound interpretation of safety or effectiveness data or may interfere with the ability to meet study requirements.
  • Any other disease or disorder that could significantly affect participation in the study. Examples may include corrected vision insufficient for viewing computer screens or hearing insufficient for following verbal instructions, which might impact the participant's ability to participate in BCI training and testing.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - 1 day

Participants undergo implantation of the Stentrode device, an endovascular electrode array that senses electrical signals from the sensorimotor cortices.

1 visit (in-person)

Post-operative Follow-up

Duration - Up to 12 months after implantation

Participants are monitored for device-related safety, including serious adverse events and vascular assessments using imaging.

Visits at 6 months and 12 months post-implant for imaging assessments and safety monitoring

Trial Site Locations

Total: 5 locations

1

Mayo Clinic

Jacksonville, Florida, United States, 32224

Actively Recruiting

2

University of Buffalo Neurosurgery

Buffalo, New York, United States, 14203

Actively Recruiting

3

Mount Sinai Hospital

New York, New York, United States, 10029

Actively Recruiting

4

University of Pittsburgh Medical Center (UPMC)

Pittsburgh, Pennsylvania, United States, 15213

Not Yet Recruiting

5

University of Texas Southwestern Medical Center (UTSW)

Dallas, Texas, United States, 75390

Not Yet Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Similar Trials

A Multiple Ascending Dose Phase 1 Study to Assess the Safety...

ALS (Amyotrophic Lateral Sclerosis)

Actively Recruiting

12 locations

ALS Translational Research Program

Amyotrophic Lateral Sclerosis

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here